BrightSpring Health Services, Inc. is a Louisville, Kentucky-based platform of home- and community-based health-care services, spanning specialty and infusion pharmacy, home health and hospice, rehabilitation, and behavioral health programs for complex Medicare, Medicaid and insured populations. The BTSGU ticker refers to the company's Tangible Equity Units — a listed, thinly traded security combining a prepaid stock purchase contract tied to BrightSpring's common stock (BTSG) with a subordinated note. The units last changed hands at $215.57 at midday Thursday, down $9.63, or 4.28%, from the previous session's close of $225.20, extending a third straight decline.
The clearest driver sits outside the company. The Centers for Medicare & Medicaid Services this week unveiled its proposed Comprehensive Regulations to Uncover Suspicious Healthcare, or CRUSH, rule, which would broaden audits of Medicare Advantage plans, allow sample findings to be extrapolated across entire contracts, and permit recovery of improper payments dating to the 2018 payment year. CMS estimates roughly $90 billion in savings over a decade, with Medicare Advantage recoveries near $9 billion per payment year. The proposal follows two sessions of aggressive selling in managed care names, with UNH down more than 10% and HUM roughly 13% on Wednesday. Uncertainty over Medicare and Medicaid funding channels also weighs on providers and pharmacy-services operators whose revenue is ultimately paid by those programs.
Minutes from the Federal Reserve's October meeting showed most officials judged further rate increases likely appropriate for a timely return of inflation to target, reinforcing expectations of a possible half-point move at the December meeting. Because each unit embeds a subordinated note alongside the stock purchase contract, the security carries duration exposure that pure equity does not; a renewed hawkish repricing therefore tends to hit these units harder than the common shares, which fell about 5.5% in the same session.
Momentum had left the units richly valued. BrightSpring's third-quarter report on October 30 delivered roughly 26% revenue growth and a raised full-year outlook, and analysts responded with constructive notes, including a BMO target increase on the common shares. The units remain up about 78% year to date and sit roughly 18.5% below their 52-week high of $255.51, reached on June 17. When a crowded, extended position meets a sector-wide risk event, the exit is rarely patient — and that dynamic was visible from the opening bell, when the units printed $223.85 and slid almost continuously to a session low of $214.70.
The decline aligned closely with the sector. The health-care select sector fund (XLV) was down about 1.5%, and the provider-focused IHF was off nearly 3% intraday, with risk-bearing provider and care-management names among the weakest. Broader indices diverged only modestly: the S&P 500 slipped about 0.6% while the Nasdaq held up better, confirming this was a health-care-specific rotation rather than a market-wide liquidation. Volume was not the story. Roughly 2,600 units had traded by late morning against a ten-day average near 33,000, and with only about 8.0 million units outstanding and a market value near $1.7 billion, thin books magnify percentage moves. Technically, the units broke below their 20-day moving average and exited the upper half of their November range, leaving the June high as the next meaningful reference point.
The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. These units earn 19 out of 100. No verified company-specific news was found: the catalyst was a sector-wide policy proposal and a macro rate signal, material to the industry but not to BrightSpring alone. The move itself was unremarkable by this security's standards — about twice the typical daily swing of 2.1% — and seven of the past 60 sessions produced equal or larger declines. Weak news plus ordinary volatility keeps the score in the low range.
Fourth-quarter results are expected in late February, when management's 2027 outlook and any commentary on reimbursement exposure will matter more than the quarter itself. Policy is the nearer catalyst: comments on the CRUSH proposal are open through January 19, 2027, and legal challenges are widely expected, so headlines could swing sentiment sharply in either direction. The December 8-9 Fed meeting will shape the rate backdrop that directly affects the note component of each unit. Risks cut both ways — supportive earnings momentum and constructive analyst coverage contrast with reimbursement uncertainty, elevated leverage, and a security that trades in very small size, which can turn modest flows into outsized moves.
Tickeron's Trending AI Robots page offers a curated view of the platform's strongest performers right now. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only those delivering the best results under current market conditions are featured here. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the selection changes as market leadership rotates. Reviewing the current lineup is a practical way to see which approaches are working in a volatile tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BTSGU's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator showed a similar pattern. In 156 of the 184 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on BTSGU as a result. In 36 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
BTSGU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for BTSGU turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 14 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.523). P/E Ratio (0.000) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.016) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.105).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BTSGU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTSGU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry